following a full submission assessed under the end of life and orphan equivalent medicine process:
nivolumab (Opdivo®) is not recommended for use within NHSScotland.
Indication under review: in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.
Nivolumab plus ipilimumab and 2 cycles of platinum-based chemotherapy significantly improved overall survival compared with platinum-based chemotherapy in patients with previously untreated stage IV or recurrent non-small cell lung cancer (NSCLC).
The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- nivolumab (Opdivo)
- SMC ID:
In combination with ipilimumab and 2 cycles of platinum-based doublet chemotherapy (PDC) is indicated for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) translocations.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Not recommended
- Date advice published
- 17 January 2022